🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Zhengzhou University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Zhengzhou University as lead sponsor. Synced 26 Sep 2026
7Current trials
2Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Zhengzhou University is the lead sponsor of 7 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 4. The drugs named most often in its trials are Axicabtagene Ciloleucel, Azacitidine and Bendamustine. The most-studied condition is Angioimmunoblastic T-cell Lymphoma (AITL).

ClinicalTrials.gov trials by status

  • Recruiting229%
  • Not yet open343%
  • Active, closed229%

Trials by phase

  • Phase 4457%
  • Observational229%
  • Phase 1/2114%
01

Clinical trials sponsored by Zhengzhou University

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
NCT05506410 · ClinicalTrials.gov ↗ · Newly Diagnosed Mantle Cell Lymphoma
Observational Recruiting 2022-08 China
Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT06609304 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell
Phase 4 Recruiting 2024-09 China
CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
NCT07117305 · ClinicalTrials.gov ↗ · CD7+ Lymphoma, T Cell Lymphoma
Phase 1/2 Not yet open 2025-09 China
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT06956092 · ClinicalTrials.gov ↗ · B Cell Lymphoma (BCL)
Phase 4 Not yet open 2025-05 China
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
NCT07264894 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL)
Phase 4 Not yet open 2025-12 China
Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight
NCT07046182 · ClinicalTrials.gov ↗ · Angioimmunoblastic T-cell Lymphoma (AITL)
Phase 4 Active, closed 2023-10 China
A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma
NCT06742879 · ClinicalTrials.gov ↗ · Follicular Lymphoma
Observational Active, closed 2024-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Zhengzhou University trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Zhengzhou University trials

8 conditions
Angioimmunoblastic T-cell Lymphoma (AITL)1Follicular Lymphoma1CD7+ Lymphoma1T Cell Lymphoma1Newly Diagnosed Mantle Cell Lymphoma1Lymphoma, B-Cell1B Cell Lymphoma (BCL)1Mantle Cell Lymphoma (MCL)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China72

A trial with sites in more than one country appears in each of those registers.

05

Questions about Zhengzhou University trials

How many clinical trials does Zhengzhou University sponsor?

Zhengzhou University is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Zhengzhou University trials recruiting?

Yes. 2 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Zhengzhou University testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Axicabtagene Ciloleucel (1), Azacitidine (1), Bendamustine (1), Cytarabine (1) and Dasatinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.